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Summary 
We tested the proliferative responses of peripheral blood mononuclear cells from 61 patients 
with multiple sclerosis, 56 healthy control subjects and 52 patients with other neurological 
diseases to seven synthetic peptides of myelin proteolipid protein (PLP) and 19 synthetic 
peptides of myelin basic protein (MBP). Increased proliferative responses to two overlapping 
PLP peptides, PLP184-199 and PLP190-209, were found significantly more frequently in blood from 
patients with relapsing–remitting or secondary progressive multiple sclerosis (52.3%), but not 
from those with primary progressive multiple sclerosis (18.2%), than in that from healthy 
control subjects (8.9%) and patients with other neurological diseases (20.8%). Reactivity to 
these PLP peptides was most frequently seen in blood from patients with multiple sclerosis of 
6–15 years duration and with moderate to severe disability (Kurtzke’s Expanded Disability 
Status Scale > 4.0); the blood from 15 of 19 patients in this group reacted to one or both of the 
peptides. Both peptides could be recognized by short-term T-cell lines specific for whole PLP, 
and lines specific for one or other of the two overlapping peptides were able to recognize whole 
PLP, indicating that these peptides can be processed naturally from the intact molecule. This 
region of PLP is encephalitogenic in a number of strains of mice. Samples from multiple 
sclerosis patients did not react more frequently to any of the MBP peptides than those from 
healthy control subjects. The proportions of patients with other neurological diseases whose 
blood responded to the MBP peptides that most frequently elicited responses in blood from 
multiple sclerosis patients were significantly lower than the proportions of multiple sclerosis 
patients and healthy control subjects whose blood responded to these peptides. 
 
Keywords: multiple sclerosis; proteolipid protein; immunoreactivity; myelin basic protein; auto-
immunity 
 
Abbreviations: ANOVA = analysis of variance; EAE = experimental autoimmune 
encephalomyelitis; EDSS = Kur tzke’s  Expanded Disability Status Scale; HLA = human leucocyte 
antigen; MBP = myelin basic protein; MHC = major histocompatibility complex; PBMC = peripheral 
blood mononuclear cells; PCR = polymerase chain reaction; PLP = myelin proteolipid protein; SI = 
stimulation index 
Introduction 
Multiple sclerosis is a human demyelinating disorder that is likely to have an autoimmune 
basis (Pender, 1995). As the demyelinated lesions in multiple sclerosis are usually restricted 
to the CNS (Lumsden, 1970; Sobel, 1995), it is likely that the target antigens of 
autoaggressive cells in multiple sclerosis are expressed primarily or exclusively in the CNS. 
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CNS myelin proteins are possible targets. The most abundant proteins of CNS myelin are 
proteolipid protein (PLP) and myelin basic protein (MBP). PLP comprises more than 50% 
ofthe protein in CNS myelin. It is expressed in small amounts (< 0.5% of total protein) by 
Schwann cells in the PNS (peripheral nervous system), but it is not incorporated into PNS 
myelin (Puckett et al., 1987). In experimental animals, immunization with PLP and adjuvants 
results in demyelinated lesions that are restricted to the CNS (Tuohy et al., 1988; Greer et al., 
1992, 1996a; Chalk et al., 1994a, b), as in multiple sclerosis. In contrast, MBP is found in 
significant quantities (20–30% of total protein) in both CNS and PNS myelin and, in 
experimental animals, immunization with MBP (or whole CNS tissue) and adjuvants or the 
passive transfer of MBP-specific lymphocytes results in demyelinated lesions in both the 
CNS and PNS (Pender and Sears, 1982, 1984; Pender, 1988a, b; Pender et al., 1989, 1995; 
Chalk et al., 1994a,b; Abromson-Leeman et al., 1995). 
A number of studies have investigated whether multiple sclerosis patients have an increased 
frequency of cells reactive to myelin antigens, including PLP or MBP, in their blood or CSF. 
These studies have been performed using a variety of methodologies and antigen preparations, 
often on only small numbers of subjects, and the results have been inconsistent. Many of these 
studies have involved the production of long-term T-cell lines and clones. Only a minority of the 
studies have looked at the immediate proliferative response of peripheral blood mononuclear 
cells (PBMC); these studies have investigated responses to whole MBP (Lisak and Zweiman, 
1977; Brinkman et al., 1982; Johnson et al., 1986; Vandenbark et al., 1989; Trotter et al., 
1991; Kerlero de Rosbo et al., 1993; Zhang et al., 1993), MBP fragments (Baxevanis et al., 
1989), whole PLP and/or two synthetic PLP peptides (Johnson et al., 1986; Trotter et al., 1991; 
Kerlero de Rosbo et al., 1993), and two quantitatively minor myelin components, MOG 
(myelin/oligodendrocyte glycoprotein) (Kerlero de Rosbo et al., 1993) and MAG (myelin-
associated glycoprotein) (Zhang et al., 1993). These have produced diverse results with little 
concurrence. 
Because there exists a correlation between the expression of the major histocompatibility 
complex (MHC) class II haplotypes, human leucocyte antigens (HLA) DR2, DW2 (HLA-
DRB1*1501, –DQA1*0102 and –DQB1*0602), and susceptibility to multiple sclerosis 
(Stewart et al., 1981; Hillert et al., 1994), it is thought that the pathogenesis of multiple 
sclerosis may involve T cells that recognize the autoantigen(s) in the context of these MHC 
class II molecules. Antigens presented by MHC class II molecules are generally 12–25 amino 
acids in length (Rammensee et al., 1995). Therefore, the aim of the current study was to assess 
the proliferative responses of freshly isolated PBMC from multiple sclerosis patients, healthy 
control subjects and patients with other neurological diseases to multiple short (12–20 amino 
acid residues) synthetic peptides of PLP and MBP, in order to determine if there is a correlation 
between multiple sclerosis and reactivity to these antigens. 
Several PLP epitopes that are immunodominant in a variety of genetically diverse mouse 
strains (Greer et al., 1996a) and in humans (Markovic-Plese et al., 1995) have not previously 
been tested for their ability to stimulate freshly isolated human PBMC, and no previous studies 
have assessed reactivity to peptides within all four major isoforms of human MBP. The use of 
synthetic peptides is particularly warranted in the case of PLP which, because of its very 
hydrophobic nature, has a strong tendency to form high molecular weight aggregates that 
readily precipitate in the presence of salts. This makes the PLP protein a poor antigen in in 
vitro tissue culture studies, as the precipitated, flocculent PLP can inhibit cell–cell contact and 
subsequent cell activation. However, Markovic-Plese et al. (1995), using multiple in vitro 
stimulations with human PLP, have found that the protein can be processed by antigen-
presenting cells into immunodominant epitopes within the 30–60 and 180–210 regions of the 
molecule. Peptides covering these regions are included in the current study. 
 
 
Methods 
Patients and control  subjects 
The subjects of this study consisted of 61 patients with clinically definite or laboratory-
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supported definite multiple sclerosis (Poser et al., 1983), 56 healthy control subjects and 52 
patients with other neurological diseases. Of the multiple sclerosis patients, 28 had relapsing- 
remitting multiple sclerosis, 19 had secondary progressive multiple sclerosis and 14 had primary 
progressive multiple sclerosis. Multiple sclerosis patients had not received corticosteroids for at 
least 2 months prior to being studied. Patients with other neurological diseases had the following 
diagnoses: epilepsy (12), Parkinson’s disease (seven), Wilson’s disease (one), Huntington’s 
chorea (one), brain tumour (three), cerebral aneurysm (two), intracranial arteriovenous 
malformation (one), cerebrovascular disease (five), hydrocephalus (one), neurofibromatosis type 
I (one), neurosarcoidosis (one), sleeping disorder (one), spinocerebellar degeneration (one), 
motor neuron disease (three), multifocal motor neuropathy (one), hereditary sensory neuropathy 
(one), Guillain-Barré syndrome (two), non-specified peripheral neuropathy (four), C8 nerve root 
lesion (one), intercostal nerve entrapment (one), myasthenia gravis (one) and proximal 
myopathy (one). 
 
Tissue typing 
Genomic DNA was prepared from Epstein–Barr-virus-transformed lymphoblastoid cell lines 
from each individual by chloroform/phenol extraction. HLA-DR typing was carried out at the 
Queensland Institute of Medical Research, Brisbane, Australia, and HLA-DQ typing at the 
Department of Immunology, Westmead Hospital, Sydney, Australia. For both HLA-DR and - 
DQ typing, DNA was initially amplified by the polymerase chain reaction (PCR) using generic 
primer pairs. Specific HLA-DRB1 alleles were then determined by hybridization of the PCR 
products with a panel of sequence-specific oligonucleotides. HLA-DQA1 and - DQB1 alleles 
were determined by restriction fragment length polymorphism analysis of the PCR products. 
 
 
 
Fig. 1.  (A) The sequence of human PLP and its proposed orientation in the oligodendrocyte cell membrane (Greer et 
al . ,  1996b) showing the peptides used in the current study in bold. (B) The four isoforms of human MBP, showing 
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the exon 2 insert (encoding 26 amino acids) in the 21.5 and 20.2 kDa isoforms, and exon 5 (encoding 11 amino acids) 
which is deleted in the 20.2 and 17.3 kDa isoforms. 
Antigens 
Human PLP was prepared from human brain white matter as previously described (Greer et al., 
1996a). PLP peptides were prepared according to the human sequence (Hudson et al., 1989) 
and were > 90% pure by HPLC analysis. The sequence of PLP showing the peptides used in the 
present study and the putative orientation of PLP in the myelin membrane is shown in Fig. 1A. 
PLP41-58 (GTEKLIETYFSKNYQDYE) and PLP95-114 (AVRQIFGDYKTTICGKGLSA) were 
synthesized at the Queensland Institute of Medical Research; PLP178-191 (NTWTTCQSIAFPSK), 
PLP184-199 (QSIAFPSKTSASIGSL) and PLP190-209 (SKTSASIGSLCADARMYGVL) were synth-
esized by Auspep (Melbourne, Australia); and PLP100-119 (FGDYKTTICGKGLSATVTGG) and 
PLP139-151 (HCLGKWLGHPDKF) were the kind gift of Dr M. B. Lees, Shriver Center, 
Waltham, Mass., USA. PLP100-119 and PLP139-151 are water-soluble. The other PLP peptides are 
moderately hydrophobic, and were dissolved at a concentration of 5 mg/ml in 0.2 M acetic acid 
prior to dilution in tissue-culture medium for proliferation assays. 
Human MBP was extracted from human brain according to the method of Deibler et al. 
(1972). Overlapping MBP peptides (numbered according to the human sequence and listed in 
Table 6) were synthesized (at the Queensland Institute of Medical Research) to represent the 
sequences of the 4 major isoforms (21.5 kDa, 20.2 kDa, 18.5 kDa and 17.3 kDa; shown in Fig. 
1B) of human MBP (Roth et al., 1987) and were > 80% pure. Peptides 5b and 5c represent the 
exon 2 insert (encoding 26 amino acids) in the 21.5 and 20.2 kDa isoforms. Peptide 10b covers 
the junctional zone formed by deletion of exon 5 (encoding 11 amino acids) in the 20.2 and 
17.3 kDa isoforms. All MBP peptides are water-soluble. 
 
 
Proliferat ion assays 
Heparinized peripheral blood (~60 ml) was collected by venepuncture from each subject after 
informed written consent had been obtained. PBMC were separated from blood by 
centrifugation through Histopaque (Sigma Chemical Co., St Louis, USA) and washed twice. 
The in vitro responses of PBMC were assayed in triplicate in 96-well round-bottomed 
microtitre plates. PBMC (2×105) and medium (RPMI 1640 containing 10% heat-inactivated 
pooled human serum, 2 mM L-glutamine, 10 mM HEPES buffer and 50 µM 2-
mercaptoethanol) with or without peptides were added to wells in a total volume of 200 µl. 
Initial studies were done using blood from five laboratory staff, all of whom had been exposed 
to both PLP and MBP for several years, and four multiple sclerosis patients to determine the 
optimal concentration of antigen to use in the main part of the study. Peptides were tested at 
concentrations ranging from 1 to 100 µg/ml. The concentrations used in the main part of the 
study (25 and 12.5 µg/ml final concentration for PLP peptides or 30 µg/ml final concentration 
for MBP peptides) were those at which the most responses occurred in the initial studies. 
Cultures were incubated for 6 days, with 0.5 µCi [3H]thymidine being added during the last 18 
h. Cultures were harvested and thymidine uptake was measured in c.p.m. (counts per minute) 
in a β-plate counter (LKB). The stimulation index (SI) was determined by the formula: SI = 
(mean c.p.m. of peptide-containing triplicate wells)/(mean c.p.m. of control triplicate wells, 
without peptide). The mean control ranged from 191 to 6071 c.p.m. A positive proliferative 
response for each sample was considered to be one in which the SI ≥ 3.0 and the mean from the 
control wells plus 3SD of the mean did not exceed the mean from the peptide-containing 
triplicate wells. 
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TABLE 1 
Characteristics Of Multiple Sclerosis Patients and Control Subjects 
 
 
 
*The peripheral blood mononuclear cells (PBMC) of some patients were only tested for reactivity to myelin 
proteolipid protein (PLP) or myelin basic protein (MBP) peptides as described in text. MS = multiple sclerosis; PP-
MS = primary progressive multiple sclerosis; RR-MS = relapsing–remitting multiple sclerosis; SP-MS = secondary 
progressive multiple sclerosis; OND = other neurological diseases; EDSS = Kurtzke’s Expanded Disability Status 
Scale; HLA-Dw2+ = percentage of individuals expressing one or more of the alleles DRB1*1501, DQA1*0102 or 
DQB1*0602. 
Generation and testing of short-term T-cell lines 
Short-term T-cell lines were prepared from three multiple sclerosis patients by incubation of 
PBMC (4×106 cells per well) with 25 µg/ml of human PLP, PLP184-199 or PLP190-209 in 24-well 
plates. Lines were restimulated 10 days later with antigen plus irradiated (3000 rad) autologous 
PBMC and then tested 12–15 days later in proliferative assays. For these assays, 5×104 T cells 
were added to 105 irradiated autologous PBMC and antigen in 96-well microtitre trays. Cultures 
were incubated for 4 days, with 0.5 µCi [3H]thymidine being added during the last 18h. 
Cultures were harvested and thymidine uptake was measured as described above. 
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Fig. 2. Percentages of healthy control subjects (HC), and patients with multiple sclerosis (MS) and other 
neurological diseases (OND), responding with SI ≥ 3.0 to PLP peptides. The P values for comparison of the 
responses of the three groups together with those for the comparisons of the pairs of groups (χ2 analysis) are shown 
directly below the peptide to which they refer. 
Statistical analysis 
Percentages of individuals making a positive proliferative response to peptides were compared 
using the χ2 test with Yates’ correction applied as required. Mean SI values were compared 
using analysis of variance (ANOVA) to compare all the groups simultaneously, followed by 
Student’s t test to compare the pairs of groups. 
 
Results 
 
Characteristics of multiple sclerosis patients and control subjects 
The characteristics of multiple sclerosis patients and control subjects are detailed in Table 1. 
PBMC from all patients with other neurological diseases and all except one multiple sclerosis 
patient that were tested for reactivity to PLP peptides were concurrently tested for reactivity to 
the MBP peptides. Seven additional multiple sclerosis patients and four additional patients with 
other neurological diseases were tested for reactivity to MBP peptides, but not PLP peptides. In 
the healthy control group, three females were tested only for reactivity to PLP peptides, and five 
males were tested only for reactivity to MBP peptides. As has previously been found for other 
groups of multiple sclerosis patients, our multiple sclerosis patients were predominantly female, 
the mean age of onset of multiple sclerosis was higher for primary progressive multiple sclerosis 
than for relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis, and 
the percentage of patients expressing the HLA-Dw2 haplotype was increased in multiple 
sclerosis patients compared with control subjects. 
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TABLE 2 
Mean Stimulation Index (SI ± SE) of PBMC from Healthy Control Subjects, Multiple Sclerosis Patients and Patients 
with Other Neurological Diseases to PLP Peptides 
 
          Peptide Healthy 
controls 
Multiple 
sclerosis 
Other neurological 
diseases 
P-value 
ANOVA* 
PLP41–58 
1.8 ± 0.4     2.2 ± 0.3** 1.6 ± 0.2 0.019 
PLP95–114 
2.9 ± 0.4 3.0 ± 0.9 2.5 ± 0.6 0.764 
PLP100–119 
1.6 ± 0.1 1.5 ± 0.1 2.5 ± 0.4 0.066 
PLP139–151 
1.2 ± 0.1 1.5 ± 0.1 2.0 ± 0.3 0.113 
PLP178–191 
1.5 ± 0.1 1.5 ± 0.2 1.9 ± 0.5 0.799 
PLP184–199 
1.7 ± 0.2 3.0 ± 0.6 2.2 ± 0.5 0.068 
PLP190–209 
1.4 ± 0.1       2.1 ± 0.2*** 1.7 ± 0.2 0.012 
*If P < 0.05 with ANOVA, then Student’s t test was used to compare pairs of groups. **Mean SI of multiple 
sclerosis patients is significantly different from the mean SI of patients with other neurological diseases (Student’s t test; 
P = 0.037), but not of healthy control subjects. ***Mean SI of multiple sclerosis patients is significantly different from 
the mean SI of healthy control subjects (P = 0.003), but not of patients with other neurological diseases. 
Reactivi ty  to PLP peptides 
Epitopes of PLP that are immunogenic in a variety of experimental animals cluster in three 
regions of the molecule (Greer et al., 1996a). Peptides covering these regions (residues 40–60, 
90–120 and 180–210), together with PLP139-151, which is an encephalitogenic epitope in SJL 
mice (Tuohy et al., 1989), were tested for their ability to induce proliferative responses with   
SI ≥ 3.0 in freshly isolated PBMC collected from 55 multiple sclerosis patients, 54 healthy 
control subjects and 48 patients with other neurological diseases. Peptides from two of the PLP 
epitope clusters (residues 40–60 and 90–120) have previously been used to derive T-cell lines 
from multiple sclerosis patients’ lymphocytes (Pelfrey et al., 1993, 1994; Correale et al., 1995; 
Markovic-Plese et al., 1995; Ohashi et al., 1995). In the present study, however, the 
percentages of multiple sclerosis patients with cells responding to peptides within these clusters 
were not significantly different from those of healthy control subjects or of patients with other 
neurological diseases (Fig. 2). However, there was a slight increase in the percentage of multiple 
sclerosis patients with cells responding to PLP41-58, and the mean SI of multiple sclerosis patients 
for PLP41-58 was significantly higher than the mean SI of cells from patients with other 
neurological diseases, but not of those from healthy control subjects (Table 2). All three groups 
showed a relatively high percentage of subjects with cells responding to PLP95-114 (Fig. 2) and 
the mean SI values for this peptide were high in all groups compared with values for other 
peptides (Table 2). This reactivity correlated strongly with the expression of the HLA-
DRB1*1101 allele: 93% of all individuals expressing this allele had cells which responded to 
PLP95-114, and ~60% of ‘responders’ in each of the three groups expressed this allele. More 
patients with other neurological diseases responded to PLP100-119 and PLP139-151 than did healthy 
control subjects or multiple sclerosis patients; however, the reactivity in patients with other 
neurological diseases did not correlate strongly with any particular disease or with expression of 
a particular HLA-DR or –DQ allele. Few subjects from any group responded to PLP178-191 (Fig. 
2 and Table 2). 
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Fig. 3. Percentages of healthy control subjects (HC), and patients with primary progressive multiple sclerosis (PP-
MS), relapsing–remitting or secondary progressive multiple sclerosis (RR/SP-MS), or other neurological diseases 
(OND), responding to PLP184-199 and/or PLP190-209. The P values are shown directly below the peptide(s) to which they 
refer (χ2 analysis). 
 
In contrast, the percentage of multiple sclerosis patients with PBMC in their blood that 
responded to PLP190-209 was significantly higher than the corresponding percentages of healthy 
control subjects and of patients with other neurological diseases (Fig. 2). The difference between 
multiple sclerosis patients and patients with other neurological diseases could not be explained 
by the predominance of males in the group of patients with other neurological diseases, as the 
percentage of male patients with other neurological diseases responding to this peptide was 
greater than the percentage of females. The percentage of multiple sclerosis patients responding 
to the overlapping peptide PLP184-199 was also increased, but only the comparison with healthy 
control subjects reached statistical significance. Reactivity to these peptides was not restricted to 
individuals expressing any particular HLA-DR or –DQ allele. The majority of responders in the 
multiple sclerosis group (91%) expressed HLA-Dw2 alleles. However, only 53% of responders 
in the control groups expressed these alleles. The expression of DRB1*1501 in combination with 
DRB1*0401, DRB1*0404 or DRB1*0701 did, however, appear to be related to increased 
responses to PLP184-199 and PLP190-209. The mean SI value of multiple sclerosis patients for 
PLP190-209 was significantly higher than that of healthy control subjects, but not of patients with 
other neurological diseases (Table 2). The mean SI of multiple sclerosis patients for PLP184-199 
was increased compared with that of healthy control subjects and that of patients with other 
neurological diseases, but comparison of the three groups by ANOVA did not reach statistical 
significance. 
Within the multiple sclerosis group, reactivity to PLP184-199 and PLP190-209 occurred most 
frequently in patients with relapsing–remitting multiple sclerosis or secondary progressive 
multiple sclerosis, who were grouped together (relapsing-remitting/secondary-progressive 
multiple sclerosis) (Fig. 3) because the results were similar in the two groups. Reactivity to 
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these peptides was found significantly more frequently in patients with relapsing-remitting/ 
secondary progressive multiple sclerosis than in healthy control subjects or patients with        
other neurological  diseases (Fig. 3).  Few patients with primary progressive multiple sclerosis 
reacted to these peptides (Fig. 3), and the mean SI values of primary progressive multiple 
sclerosis patients for these peptides were significantly lower than those of patients with 
relapsing–remitting/secondary progressive multiple sclerosis (Table 3). The highest frequency 
of reactivity to PLP184-199 and/or PLP190-209 occurred in those relapsing–remitting/secondary 
progressive multiple sclerosis patients who had a disease duration of 6–15 years (Fig. 4). 
Fifteen of 19 patients with this duration of disease responded to one or both peptides. The 
mean SI values of patients with relapsing–remitting/secondary progressive multiple sclerosis 
peaked in the 11–15 years duration group, at which time the mean SI values were significantly 
different from those of both healthy control subjects and patients with other neurological 
diseases (Table 4). The differences between primary progressive multiple sclerosis patients and 
relapsing–remitting/secondary progressive multiple sclerosis patients are unlikely to be solely 
due to the shorter disease duration in primary progressive multiple sclerosis patients, as the 
mean SI values for primary progressive multiple sclerosis patients with a disease duration of 
6–11 years were substantially lower than those for patients with relapsing–remitting/secondary 
progressive multiple sclerosis with a duration of 6–10 years (Table 4). 
To determine whether the PLP184-199 and PLP190-209 peptides can be naturally processed 
from the whole PLP molecule, short-term T-cell lines specific for whole human PLP, PLP184-199 
or PLP190-209 were prepared from three multiple sclerosis patients who responded to these 
peptides in the initial assays. The T-cell lines were then tested for their ability to proliferate in 
response to the three antigens. Short-term PLP-specific lines from multiple sclerosis patient 22 
and multiple sclerosis patient 45 showed increased responses to PLP184-199 and PLP190-209; 
however, the PLP-specific line from multiple sclerosis patient 35 did not respond significantly 
to either peptide (Table 5). All of the lines specific for PLP184-199 responded significantly to all 
three antigens. In contrast, the response of PLP190-209-specific lines was variable, with lines 
from multiple sclerosis patient 22 and multiple sclerosis patient 45 responding significantly 
only to PLP190-209, whereas the line from multiple sclerosis patient 35 responded to whole PLP 
and PLP184-199, in addition to PLP190-209. As predicted from previous experience with PLP (as 
described in the Introduction), whole PLP was unable to induce responses of the same 
magnitude as the peptides, even when the T-cell line was generated against the whole 
molecule. Nevertheless, there were significant responses to whole PLP by at least one peptide-
specific line from each of the three multiple sclerosis patients, indicating that whole PLP can 
be naturally processed into epitopes within the 184-209 region of the molecule. The results 
suggest that there are at least two dominant naturally processed epitopes of PLP, one in the 
overlapping 190–199 region and one present only in PLP184-199. 
 
TABLE 3 
Mean Stimulation Index (SI ± SE) of PBMC From Primary Progressive Multiple Sclerosis (PP-MS) 
Patients, Relapsing-Remitting or Secondary Progressive Multiple Sclerosis (RR/SP-MS) Patients, Healthy 
Controls And Patients With Other Neurological Diseases 
*ANOVA was used to compare PP-MS and RR/SP-MS patients, patients with other neurological diseases and 
healthy controls. **Mean SI of RR/SP-MS patients is significantly different from the mean SI of healthy control 
subjects (Student’s t  test; P = 0.018), and of PP-MS patients (P = 0.033), but not of patients with other 
neurological diseases. ***Mean SI of RR/SP-MS patients is significantly different from the mean SI of healthy 
control subjects (P = 0.002) and of patients with other neurological diseases (P = 0.05), and from that of PP-MS 
patients (P< 0.001). 
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Fig. 4. Relationship between responsiveness of PBMC to PLP184-199 and/or PLP190-209 and duration of relapsing- 
remitting or secondary progressive multiple sclerosis (RR/SP-MS) and EDSS score (filled circles). The number of 
individuals for each duration was: 0–5 years, n = 11; 6–10 years, n = 9; 11–15 years, n = 10; 16–20 years, n = 4; 
>20 years, n = 10. 
TABLE 4 
Mean Stimulation Index (SI ± SE) Of PBMC from Patients With Relapsing-Remitting Or Secondary 
Progressive Multiple Sclerosis (RR/SP-MS) and Primary Progressive Multiple Sclerosis (PP-MS) of 
Different Disease Durations 
 
When ANOVA was used to compare healthy control (HC) subjects, patients with other neurological diseases (OND), 
the five groups of RR/SP-MS patients and the two groups of PP-MS patients, then P < 0.000035 for each peptide. 
* P < 0.048 when compared with HC subjects (in Student’s t test), but not significant compared with OND patients. 
* * P = 0.003 when compared with HC subjects, but not significant compared with OND patients. * * * P < 0.002 
compared with both HC subjects and OND patients. 
 
React iv i ty  to  MBP and  MBP pept ides  
The responses of PBMC from 61 multiple sclerosis patients, 56 healthy control subjects and 52 
patients with other neurological diseases to 19 overlapping 20-amino acid-residue peptides of 
MBP were also tested in proliferation assays. There were no significant differences between the 
percentages of multiple sclerosis patients and healthy control subjects responding with SI ≥ 3.0 to 
the MBP peptides, except for MBP11–30, which elicited a response in a significantly higher 
percentage of healthy control subjects than of multiple sclerosis patients (Table 6). PBMC from 
multiple sclerosis patients responded most frequently to peptides 5b, MBP82-100, MBP91-110 and 
MBP101-120;  however, similar percentages of PBMC from healthy control subjects  responded  to 
these peptides. In the multiple sclerosis group, 83%, 85%, 85% and 100%, respectively of 
patients responding to peptides 5b, MBP82-100, MBP91-110 and MBP101-120 expressed 
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at least one HLA-Dw2 allele. However, in the control group, only 36%, 33%, 47% and 
42%, respectively of responders to peptides 5b, MBP82-100, MBP91-110 and MBP101-120 
expressed HLA-Dw2 alleles. Interestingly, the percentages of PBMC from patients with 
other neurological diseases responding to peptides 5b and MBP82-100 were significantly 
reduced compared with those of healthy control subjects and multiple sclerosis patients 
(Table 6). These differences could not be explained by the predominance of males in the 
group of patients with other neurological diseases. There was no obvious relationship 
between responses to peptide 5b and the duration of multiple sclerosis; however, the 
highest percentage of responders to MBP82-100 was in the group with disease duration of ≤ 
5 years (Fig. 5). Analysis of the responses of the primary progressive multiple sclerosis, 
relapsing–remitting multiple sclerosis and secondary progressive multiple sclerosis 
subgroups did not reveal any differences in reactivity to the MBP peptides among the 
groups. The percentage of multiple sclerosis patients reacting to whole MBP was 
intermediate between the percentages of healthy control subjects and patients with other 
neurological diseases, but the differences were not significant (Table 6). The mean SI 
values for the MBP peptides and MBP (Table 7) showed the same pattern of reactivity as 
that indicated by the χ2 analysis. 
 
Discussion 
This study indicates that there is increased reactivity against PLP184-199 and PLP190-209 in 
relapsing-remitting multiple sclerosis and secondary-progressive multiple sclerosis patients, 
but not primary-progressive multiple sclerosis patients, compared with healthy control 
subjects and patients with other neurological diseases (Fig. 3). Although stimulation assays 
with synthetic peptides can potentially introduce a bias for cryptic epitopes, we have shown 
that PLP184-199-specific T cells and PLP190-209-specific T cells can respond to whole PLP and 
vice versa, indicating that these epitopes of PLP can be processed naturally from whole PLP by 
antigen-presenting cells of multiple sclerosis patients. Autoimmune responses to epitopes 
within the same region of PLP (residues 178–209) mediate experimental autoimmune 
encephalomyelitis (EAE) in a variety of mice of different genetic backgrounds (Greer et al., 
1992, 1996a). We did not find a correlation between PBMC proliferative responses to MBP 
peptides and multiple sclerosis. However, the differences in responses of multiple sclerosis 
patients and patients with other neurological diseases to MBP peptides do raise some 
questions regarding regulation of responses to MBP, which will be discussed below. 
 
TABLE 5 
Reactivity Of Short-Term T-Cell Lines To Whole Myelin Proteolipid Protein (PLP), PLP184–199  or  PLP 1 9 0 – 2 0 9  
 
 
*Positive responses. 
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TABLE 6 
Percentage Of Subjects Responding To Myelin Basic Protein (MBP) and MBP Peptides 
 
 
 
The 3×2 χ2 analysis was significant (P < 0.05) for peptides 2, 4, 5b, and 9, but not for the other peptides. *Percentage of 
healthy control subjects (HC) responding to peptide is significantly different from the percentages of both multiple 
sclerosis patients (MS) (P < 0.001, χ2) and patients with other neurological diseases (OND) (P = 0.002) responding to 
the same peptide. **Percentage of OND patients responding to peptide is significantly different from the percentages of 
both MS patients and healthy control subjects responding to the same peptide (P < 0.02). 
 
 
 
Fig. 5. Relationship between responsiveness to MBP peptide 5b and MBP82–100 and duration of multiple sclerosis. The 
number of individuals for each duration was: 0–5 years, n = 16; 6–10 years, n = 18; 11–15 years, n = 14; >16 years, n = 
13. 
Autoreact ivi ty to PLP 
 
Three previous studies have investigated proliferative responses of PLP-specific lymphocytes in 
the blood of multiple sclerosis patients. Two of these studies reported no differences between 
multiple sclerosis patients and control subjects (Johnson et al., 1986; Kerlero de Rosbo et   al., 
1993), whereas Trotter et al. (1991) showed a difference between the responses of chronic 
Brain (1997) 120 (8): 1447-1460.                                                                             http://dx.doi.org/10.1093/brain/120.8.1447 
 
progressive (primary progressive + secondary progressive) multiple sclerosis patients and 
healthy control subjects to whole PLP. None of these studies investigated the response to 
peptides within the 180–210 region of the molecule. In the two studies (Johnson et al., 1986; 
Kerlero de Rosbo et al., 1993) that found no differences between multiple sclerosis patients and 
control subjects, bovine PLP was used, whereas in the study of Trotter et al. (1991) human 
PLP was used. PLP is a highly conserved molecule; there is < 1% difference in PLP among 
mammalian species, and murine and human PLP are completely identical (Macklin et al., 1987; 
Hudson et al., 1989). Bovine PLP, however, differs from human PLP at residues 88, 188 and 
198 (Laursen et al., 1984). These differences could affect the ability of human T cells to 
respond to bovine PLP, particularly since two of these differences occur in the region of the 
molecule that we have identified in the present study as being a target of autoreactive cells in 
multiple sclerosis. It is known that one of the murine encephalitogenic epitopes within the 180–
209 region, PLP178–191, is encephalitogenic in SJL mice only when synthesized according to the 
murine sequence; it is not encephalitogenic when synthesized according to the bovine sequence 
(Greer et al., 1997). In addition, in this murine model, mice immunized with murine PLP or the 
murine peptide respond only to murine PLP/peptide in proliferation assays; there is no cross-
reactivity with the bovine peptide. Thus, if a similar situation occurs in humans, responses to 
epitopes in this region could be missed if bovine PLP is used as the stimulating antigen. 
Interestingly, Trotter et al. (1991) found that the percentage of patients with early (disease 
duration of ≤ 2 years) and low-disability (EDSS < 3.0) relapsing–remitting multiple sclerosis 
reacting to PLP was lower than that of patients with more severe progressive disease. This is in 
agreement with the present study, in which we found that the greatest reactivity to PLP184–199 
and/or PLP190–209 occurred in relapsing–remitting multiple sclerosis and secondary progressive 
multiple sclerosis patients with a disease duration of 6–15 years. The low frequency of 
reactivity to PLP peptides in patients with a short disease duration may indicate that the 184–
209 region of PLP is not the target of the initial autoimmune attack in most cases of multiple 
sclerosis. Reactivity to this region of PLP might develop only after substantial myelin damage 
has occurred. Alternatively, the frequency of specific lymphocytes in the periphery may have 
been low if the disease was quiescent when PBMC were collected. 
TABLE 7 
Mean SI ± SE Of PBMC of Healthy Controls, Multiple Sclerosis Patients and Patients With Other 
Neurological Diseases For MBP and MBP Peptides 
 
 
*Mean SI of healthy control (HC) subjects is significantly different from mean SI of multiple sclerosis (MS) patients 
(Student’s t test; P < 0.049) and patients with other neurological diseases (OND) (P < 0.021). **Mean SI of OND 
patients is significantly different from mean SI of MS patients (P < 0.04) and HC subjects (P < 0.002). 
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The association  between  multiple  sclerosis  and  the expression of HLA-DRB1*1501,  
–DQA1*0102 and –DQB1*0602 (Dw2) alleles (Hillert et al., 1994) suggests that the target 
antigen(s) in multiple sclerosis may have a high affinity for these molecules, in the same way 
that certain self peptides preferentially bind to HLA molecules associated with the autoimmune 
disease pemphigus vulgaris (Wucherpfennig et al., 1995). The majority of relapsing-remitting 
multiple sclerosis and secondary progressive multiple sclerosis patients reacting to PLP184–199 or 
PLP190–209 expressed these multiple sclerosis-associated alleles. However, our results suggest 
that the development of reactivity to PLP184–199 and/or PLP190–209 may be related to the presence 
of other alleles in the genotype, in particular DRB1*0401, DRB1*0404, or DRB1*0701 (or 
other alleles in linkage disequilibrium with them). The most common genotype encountered in 
the group of multiple sclerosis patients tested in this study, HLA-DRB1*0301,1501, did not 
correlate with reactivity to the two peptides. Previous binding assays have shown that PLP180–199 
and PLP190–209 bind with relatively high affinity to a variety of murine (Greer et al., 1996a) and 
human class II MHC molecules, including HLA-DRB1*1501, DR4 and DRB4 (DR53), but not 
DR3 (Markovic-Plese et al., 1995). Interestingly, Ito et al. (1996) have recently shown that 
transgenic mice expressing the human HLA-DR4 molecule are susceptible to induction of EAE 
with PLP175–192, an epitope overlapping PLP184–199. Markovic-Plese et al. (1995) also showed 
that PLP184–199 is a dominant region recognized by human T cells (control and multiple 
sclerosis) that have been stimulated several times in vitro with PLP (Markovic-Plese et al., 
1995). We have also found that whole-PLP-stimulated T-cell lines can recognize both PLP184–
199  and PLP190–209 and, in addition, that T-cell lines specific for these peptides can recognize the 
whole PLP molecule (Table 5). The specific epitopes recognized will depend largely on the 
particular HLA genotype of the individual. These results clearly demonstrate that the intact PLP 
molecule can be naturally processed into epitopes contained within the PLP184–199 or PLP190–209 
peptides. These features of the immune response to PLP may allow susceptible individuals to 
develop increased reactivity to PLP, once myelin breakdown has occurred. 
As already mentioned, PBMC from most of the primary progressive multiple sclerosis 
patients did not respond to PLP184–199 or PLP190–209. Several studies have suggested that 
primary progressive multiple sclerosis differs from relapsing–remitting and secondary 
progressive multiple sclerosis (Confavreux et al., 1980; Verjans et al., 1983; Larsen et al., 
1985; Poser et al., 1986; Olerup et al., 1989; Thompson et al., 1991; Revesz et al., 1994). 
Both histological (Revesz et al., 1994) and MRI (Thompson et al., 1991) findings indicate that 
there is less inflammation in primary progressive multiple sclerosis than in the other forms of 
multiple sclerosis. It has also been suggested that expression of certain HLA genes, in addition 
to the Dw2 susceptibility alleles, may predispose towards primary progressive multiple 
sclerosis (Olerup et al., 1989), although this evidence is inconclusive. Furthermore, primary-
progressive multiple sclerosis and relapsing–remitting/secondary progressive multiple sclerosis 
also differ in the age of onset (Confavreux et al., 1980; Verjans et al., 1983), initial symptoms 
(Confavreux et al., 1980; Larsen et al., 1985) and prognosis with regard to disability 
(Confavreux et al., 1980; Verjans et al., 1983) and mortality (Poser et al., 1986). Our present 
results support the notion that primary progressive multiple sclerosis differs from relapsing–
remitting multiple sclerosis and secondary progressive multiple sclerosis. 
 
Autoreact iv i ty  to  MBP 
Some previous studies of the PBMC proliferative responses to MBP or MBP fragments have 
shown significantly higher reactivity to MBP in multiple sclerosis patients than in normal 
control subjects or patients with other neurological diseases (Lisak and Zweiman, 1977; 
Brinkman et al., 1982; Baxevanis et al., 1989; Vandenbark et al., 1989), but other studies have 
not (Johnson et al., 1986; Kerlero de Rosbo et al., 1993). Zhang et al. (1994) have reported 
that there is an increased frequency of IL-2-responsive T cells specific for MBP in peripheral 
blood and CSF of multiple sclerosis patients. In the present study, the proportion of multiple 
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sclerosis patients reacting to whole MBP was intermediate between the proportions of healthy 
control subjects and patients with other neurological diseases, but the differences were not 
significant. 
In the present study, the peptides that were recognized most often by PBMC from 
multiple sclerosis patients were MBP82–100, MBP91–110, MBP101–120 and peptide 5b which covers a 
region expressed in the 21.5 and 20.2 kDa isoforms of MBP. Previously, we (Pender et al., 
1996) and others (Martin et al., 1990; Ota et al., 1990; Zhang et al., 1992) have found that 
MBP82–100 (which is the same sequence as the peptide numbered MBP84–102 by Ota et al., 1990) 
is an immunodominant region, as T cells stimulated with whole MBP frequently react with 
peptides in this region. Valli et al. (1993) showed that MBP82–100 is promiscuous in its ability to 
bind with high affinity to many different HLA-DR molecules. In contrast, they found that 
MBP101–120 binds with only low affinity to several HLA-DR molecules, including HLA-
DRB1*1501. Not all individuals expressing HLA-Dw2 alleles reacted to MBP82–100, MBP91–110, 
MBP101–120, and peptide 5b but, of those multiple sclerosis patients who did react, nearly all 
expressed Dw2. 
Similar proportions of healthy control subjects and multiple sclerosis patients had 
PBMC that recognized MBP82–100, MBP91–110, MBP101–120 and peptide 5b, but the proportions of 
patients with other neurological diseases responding to these peptides were considerably lower. 
We have suggested that multiple sclerosis might result from an inability to delete autoreactive T 
cells in the CNS (Tabi et al., 1995). One possible explanation for our findings is that, in healthy 
control subjects, these MBP-reactive cells make a primary response to the peptides in vitro; in 
patients with other neurological diseases, in whom some damage to the CNS or PNS has 
occurred, the T cells have already encountered the MBP peptides in vivo and have been deleted 
in the nervous system, as occurs during spontaneous recovery from EAE (Tabi et al., 1994, 
1995); whereas, in multiple sclerosis patients, these T cells have not been deleted, even after 
repeated exposure to antigen in vivo. The same pattern of responses was not observed with all 
PLP peptides. However, this may be due to the absence of PLP in PNS myelin, and a 
consequent lack of deletion of PLP-reactive cells in patients with other neurological diseases of 
the PNS. Further study of the activation status of the responding cells from healthy control 
subjects, multiple sclerosis patients, and patients with other neurological diseases to certain 
MBP and PLP peptides will be required to resolve this issue. The lack of increased reactivity to 
MBP peptides in patients with multiple sclerosis might have been anticipated from the fact that 
EAE induced by immunization with MBP (or whole CNS tissue), or by the passive transfer of 
MBP-sensitized lymphocytes, is characterized by major involvement of the proximal PNS 
(Pender and Sears, 1982, 1984; Pender, 1988a, b; Pender et al., 1989, 1995; Chalk et al., 
1994a, b; Abromson-Leeman et al., 1995), which does not occur in typical multiple sclerosis. 
 
Conclusions 
In the present study we have demonstrated increased T-cell reactivity to two overlapping 
PLP peptides in patients with relapsing–remitting or secondary progressive multiple sclerosis, 
but not primary progressive multiple sclerosis. Both of the peptides can be processed naturally 
from the intact PLP molecule. The region of PLP that is the target of this autoreactivity is 
encephalitogenic in a wide variety of mice of different genetic backgrounds. It is also a region 
in which species differences in the PLP sequence occur, and this may account for the failure of 
two previous studies, which used bovine rather than human PLP, to identify PLP as a target of 
autoreactive cells in the blood of multiple sclerosis patients. The strongest and most frequent 
reactivity to these PLP peptides occurred in those relapsing– remitting multiple sclerosis and 
secondary progressive multiple sclerosis patients with multiple sclerosis of 6–15 years duration 
and with moderate to severe disability. In contrast, multiple sclerosis patients did not react 
more frequently to any of the MBP peptides than did healthy control subjects, suggesting that 
in the majority of cases of multiple sclerosis, autoreactivity to MBP may not play a significant 
role in the disease process. It remains to be determined whether T-cell responses to these PLP 
peptides play a pathogenic role in multiple sclerosis. 
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